Arovella Therapeutics Ltd (ASX:ALA) CEO and managing director Dr Michael Baker joins Proactive to recap a busy quarter of development for the biotech company, which is focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. During the quarter, Arovella finalised a clinic-ready manufacturing process for ALA-101 and the CAR-iNKT cell platform at Cell Therapies Pty Ltd. This semi-automated process, crucial for large-scale Good Manufacturing Practice (GMP) production, ensures a high yield and purity of CAR-positive iNKT cells. The process is designed to be reproducible and aligns with regulatory expectations, enhancing the product's potential for approval and reducing technology transfer risks. Key milestones expected in the next 12 months include manufacturing clinical batches of ALA-101, securing regulatory acceptance for Phase 1 clinical trials in CD19-positive blood cancers, and presenting preclinical data for gastric cancer and IL-12-TM programs. The company holds $12.7 million in funding as of 30 June 2024, ensuring financial stability to obtain preliminary data in its planned first-in-human trials. Arovella's preparations for its Phase 1 clinical trial to treat CD19-positive blood cancers include the recent presentation of preclinical data at the AACR Annual Meeting, detailing the distinct phenotypes and cytotoxic abilities of CD4+ and CD4- CAR-iNKT cells. The company also strengthened its team with notable appointments, including Dr Michelle Ferguson and Dr Kelvin Yip, and added Professor Gianpietro Dotti to its Scientific Advisory Board. #ProactiveInvestors #ArovellaTherapeutics, #ASX #ALA #CancerTreatment, #iNKTCellTherapy, #ClinicalTrials, #ALA101, #CARiNKT, #GMPManufacturing, #CD19, #FDAApproval, #BiotechNews, #CellTherapy, #Immunotherapy, #PreclinicalData, #AACR, #BloodCancer #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews